" /> Pegcetacoplan - CISMeF





Preferred Label : Pegcetacoplan;

Obsolete resource : true;

NCIt definition : A pegylated peptide inhibitor of human complement components C3 and C3b, with potential use as a treatment for various diseases in which excessive complement activation plays a key role, including paroxysmal nocturnal hemoglobinuria (PNH), geographic atrophy (GA), cold agglutinin disease (CAD), and C3 glomerulopathy (C3G). Upon administration, pegcetacoplan selectively binds to C3 and C3b and inhibits their activities. This prevents complement pathway activation, and inhibits complement-mediated inflammation and cell lysis. Excessive complement activation plays a key role in various inflammatory and autoimmune diseases, and leads to tissue destruction. C3 is a key component of the complement system, and the complement system is an integral component of the innate immune response.;

NCIt note : See 'Pegcetacoplan(C121135)';

Concept status : Retired_Concept;

UNII : TO3JYR3BOU;

CAS number : 2019171-69-6; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2019171-69-6 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Molecule name : APL 2; APL-2;

NCI Metathesaurus CUI : CL1382535;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
07/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.